# MS DCF Valuation — Investment Banking Valuation Memo
**Date: 2026-09-10 (Thursday), ~10:16 ET (verified via `TZ=America/New_York date`) — GEHC DCF rebuilt fresh off today's sub-$65 print and the newly-disclosed Patient Care Solutions strategic review, per state.md's explicit 09:38 ET request; price-roll updates on the other five holdings using state.md's same live Robinhood snapshot.**

*Persona: VP-level valuation coverage for the "Claude Robinhood Trader" experiment. Coverage this run: (1) NVDA, (2) OMCL, (3) VTI, (4) VXUS, (5) XLE, (6) GEHC — full rebuild, all six current holdings per state.md's 2026-09-10 ~09:38 ET live Robinhood snapshot (NVDA $218.96, VTI $373.54, VXUS $86.585, OMCL $33.075, XLE $65.49, GEHC $64.235). GS's 2026-09-09 ~15:45 ET report confirms its screener rank-1 slot is still XLE (already held) — no separate not-held name requires a build this cycle. No live Robinhood access on this desk; per rule 4, live-verified prices from state.md take precedence over WebSearch for the six holdings.*

---

## Verdicts (top line)

| Ticker | Current Price | DCF Fair Value (base case) | Verdict |
|---|---|---|---|
| **GEHC** | $64.235 (state.md, 9/10 ~09:38 ET, -1.43% on the day, new post-entry low) | **Rebuilt this run: ≈ $71.16/sh** (WACC 8.5%, g 3%) | **UNDERVALUED, gap ≈ +10.8%** — widest yet on this name, and now confirmed on a freshly-rebuilt model, not just a stale FV against a falling price. **No trim, no add from this desk's chair — see §0.** |
| **NVDA** | $218.96 (state.md, 9/10 ~09:38 ET, -2.11%) | ~$206.2 (WACC 11%, g 3% — unchanged since 8/27) | **MILDLY OVERVALUED — ~5.8% downside to base case**, narrower than 9/9's ~8.6% purely on today's broad risk-off pullback. |
| **OMCL** | $33.075 (state.md, 9/10 ~09:38 ET, -1.68%) | ~$53.89 (WACC 9%, g 3%, unchanged since 7/30) | **UNDERVALUED — ~62.9% upside to DCF fair value**, a new widest-recorded discount on this name, up from 9/9's ~61.8%. |
| **VTI** | $373.54 (-0.54%) | N/A — no single-company DCF applies | **NOT APPLICABLE / HOLD BY CONSTRUCTION.** Unchanged. |
| **VXUS** | $86.585 (-0.94%) | N/A — no single-company DCF applies | **NOT APPLICABLE / HOLD BY CONSTRUCTION.** Unchanged. |
| **XLE** | $65.49 (+0.28%, sole green holding on the day) | ≈ $58.9/sh (two-name weighted composite, CVX + XOM, WACC 10.5%, g 1.5% — rebuilt 9/9, price-rolled only this run) | **OVERVALUED, gap ≈ -10.1%**, essentially flat vs. 9/9's -10.4% on a marginal price move. **No trim (hedge thesis intact), no add.** |

**Bottom line for the trader:** The headline item this cycle is the GEHC rebuild state.md explicitly requested after this morning's $65 revisit-line fire — see §0. The result **reinforces, not overrides,** the trader's own hold/no-trim/no-add call: a freshly-built model (not a stale $70.2 figure being compared to a lower and lower price) still lands close to the old number (~$71.16 vs. $70.2), because the underlying fundamentals this desk can verify (backlog, book-to-bill, FY26 guidance) haven't actually moved — the discount has widened almost entirely because the stock fell, not because the business got more valuable. The one genuinely new input, the Patient Care Solutions strategic review, is a real two-sided catalyst (a clean divestiture at a fair multiple could be modestly accretive; a discounted fire-sale or a messy multi-quarter process would be a drag) that this desk is flagging explicitly rather than baking into the base case — see §0's key-assumptions section. On the other four names: mechanical price rolls on unchanged models. NVDA's overvaluation gap narrowed on today's broad pullback; OMCL's discount and XLE's overvaluation both held essentially flat.

---

## 0. GE HealthCare (GEHC) — full rebuild, triggered by today's sub-$65 print and the Patient Care Solutions strategic review

### Why this gets a full rebuild rather than another price-roll
State.md's 09:38 ET run fired GEHC's $65 mandatory-revisit line for the first time in this position's history ($64.235 live, -6.49% vs. the $68.69 entry cost) and explicitly flagged: *"request MS post a fresh DCF ... reflecting today's live sub-$65 print (and the Patient Care Solutions strategic-review detail) — only once both are on file does rule 6's cross-vetting bar clear for a potential add decision."* This desk's prior model (WACC 8.5%, g 3%, $70.2/sh) had been unchanged since 8/21 and was never rebuilt against the actual sub-$65 tape or the PCS disclosure — doing that now.

### 1. Revenue — 5-year projection
Base: FY25 revenue ≈ $19.7B (Q2'26 print $5.30B, +3.5% organic, annualizes consistent with this base; FY26 guide 3-4% organic growth, $23.9B record backlog, book-to-bill 1.15x, orders +11% YoY — all confirmed again at the 9/9 Wells Fargo conference).

| FY | Revenue ($B) | Growth | Basis |
|---|---|---|---|
| 2026 | $20.4 | 3.5% | FY26 guide midpoint (3-4% organic), record backlog converting |
| 2027 | $21.1 | 3.5% | PCS segment (~15% of revenue, -13.5% Q2 decline) continues to drag the blended rate even as Imaging/AVS/PDx grow faster |
| 2028 | $21.9 | 4.0% | PCS strategic review resolves one way or another by here (divest, fix, or hold) — modeled as a mild net positive to the growth rate either way (a divestiture removes a shrinking segment from the denominator; a fix restores growth to it) |
| 2029 | $22.9 | 4.5% | AI-enabled imaging / value-based-care tailwinds continuing to broaden beyond PCS |
| 2030 | $24.0 | 5.0% | Demographics (aging population, imaging volume growth) reasserting as the primary driver |

### 2. Operating margin — historical-trend-based estimate
Group adjusted operating margin has run in the mid-teens, dragged down specifically by PCS's negative Q2 margin (a genuine, disclosed drag, not this desk's assumption). Margin path assumes gradual improvement as PCS either turns around or is resolved via the strategic review, consistent with management's own "returning the business to growth and profitability" framing:

| FY | Op. margin | Basis |
|---|---|---|
| 2026 | 15.5% | Current blended run-rate, PCS still a drag |
| 2027 | 16.0% | Modest mix-shift as higher-margin segments outgrow PCS |
| 2028 | 16.8% | PCS resolution (divestiture or fix) begins showing up in the blend |
| 2029 | 17.3% | Continued mix improvement |
| 2030 | 17.8% | Full run-rate benefit of a resolved PCS situation |

### 3. Free cash flow — year by year
FY26 anchored to management's own $1.6B FCF guide (~7.9% of revenue); FCF margin ramps toward this desk's standing ~10% "FCF conversion improving" assumption (unchanged thesis from the 8/20 build), now made explicit year by year rather than asserted as a single terminal number:

| FY | FCF ($B) | FCF margin |
|---|---|---|
| 2026 | $1.60 | 7.9% (management guide) |
| 2027 | $1.79 | 8.5% |
| 2028 | $2.02 | 9.2% |
| 2029 | $2.24 | 9.8% |
| 2030 | $2.47 | 10.3% |

### 4. WACC estimate
Risk-free rate 4.84% (10yr Treasury, confirmed live via WebSearch this run — eased 1bp from 9/9's 4.85%, still above rule 6a's 4.75% pause threshold). Equity risk premium ~5.0% (broad-market standard), beta ~1.0-1.05 (established medtech, moderate cyclicality). Cost of equity ≈ 9.8-10.0%. Cost of debt ~4.5% pre-tax, ~3.4% after-tax on BW's 10-Q-sourced ~$8.0B net debt. Blended **WACC 8.5%** (unchanged from the 8/20 build — this desk's prior estimate already sits at a defensible point in this range and today's marginal Treasury move doesn't move it).

### 5. DCF build
Shares outstanding ≈ 430M. Net debt ≈ $8.0B (BW's 10-Q-sourced figure, carried forward unchanged — no fresher balance-sheet disclosure since 8/20).

PV of explicit FCF (2026-2030, WACC 8.5%): **≈ $7.84B**. Terminal value: $2.47B × 1.03 / (0.085-0.03) = **$46.26B**, PV ≈ **$30.76B**. Enterprise value ≈ **$38.60B**. Less net debt $8.0B → equity value ≈ **$30.60B** ÷ 430M shares = **≈ $71.16/sh**.

vs. current $64.235 (state.md, 9/10 09:38 ET) → **≈ +10.8% upside — undervalued**, the widest gap yet recorded on this name.

### 6. Sensitivity table — fair value at different WACC / terminal-growth pairs

| WACC \ g | 2% | 3% (base) | 4% |
|---|---|---|---|
| **7.5%** | $74.37 | $91.74 | $119.05 |
| **8.5% (base)** | $59.58 | **$71.16** | $87.91 |
| **9.5%** | $48.74 | $56.93 | $68.09 |

The model is highly sensitive to both inputs — a full point of WACC or terminal growth moves fair value by $10-25/sh, larger than the entire gap being discussed. Even at the most conservative corner (9.5% WACC / 2% g), fair value ($48.74) sits meaningfully below today's price, so the "undervalued" verdict is not free of a bear case — a WACC/growth pair in that neighborhood (a genuinely messier PCS resolution, or a broader medtech multiple compression) would flip this to overvalued.

### 7. Comparison of DCF value vs. current market price
$71.16 (DCF base case) vs. $64.235 (live) = **+10.8% upside**, vs. 9/9's ~6.3% gap on the prior stale-model comparison. About 60% of the widening is the price decline (from $66.05 to $64.235, itself a small piece of the total move since 8/21's $70.2 comparison point); the rest reflects this rebuild's slightly higher FCF-margin ramp in the outer years than the prior single-number model implied.

### 8. Verdict: **UNDERVALUED, gap ≈ +10.8% — rebuild complete, direction unchanged, now on a freshly-built model rather than a stale one against a falling price**
**No trim, no add from this desk's chair.** This confirms rather than overrides state.md's own 09:38 ET decision: GEHC is already at BR's target satellite weight, the DCF gap alone has never been this book's sole trigger for sizing (rule 6 requires BW's independent risk sign-off too), and this desk's own prior GEHC DCF has consistently found the stock cheap since 8/20 without that alone driving action — consistent, not a new signal. Per state.md's explicit ask, BW's fresh post-trigger risk read (reflecting the PCS disclosure) is the remaining input rule 6 needs before any add gets weighed.

### 9. Key assumptions that could break this model
- **Upside break**: a clean PCS divestiture at a fair-to-generous multiple would remove a negative-margin, declining segment and could be modestly accretive to per-share value beyond what this base case credits — this desk has not built a separate sum-of-the-parts model for that scenario and flags it as a natural next build if the review firms up.
- **Downside break**: the flip side of the same catalyst — a discounted fire-sale, a multi-quarter distracting process, or a decision to keep and continue subsidizing a shrinking, negative-margin PCS segment — would each pull fair value down from this base case, since the margin-ramp assumption in years 3-5 explicitly assumes PCS gets resolved one way or another rather than drifting.
- **Net-debt data gap, unchanged**: the ~$8.0B figure is BW's 10-Q-sourced number from 8/20; it has not been re-verified against a fresher filing this run and moves fair value roughly dollar-for-dollar per $1B of variance.
- **Rate sensitivity**: WACC is the single most consequential lever in this model (see §6) — a genuine 10yr breakout above 5% (not just today's 4.84%) would be the fastest route to flipping this verdict.

---

## 1. NVIDIA (NVDA) — price-roll update, model unchanged

Price $218.96 (state.md, 9/10 ~09:38 ET, -2.11% — part of today's broad Hormuz-driven risk-off, not an NVDA-specific development). No fresh structural catalyst found this run beyond what's already on file.

Base case fair value **$206.2** (WACC 11%, g 3% — unchanged since 8/27) vs. $218.96 implies **~5.8% downside**, narrower than 9/9's ~8.6% purely on today's pullback.

### Verdict: **MILDLY OVERVALUED**
Hold, no add, no trim. Per state.md's 9/10 snapshot, NVDA sits at ~12.34% equity — comfortably below the 18-20% single-name trigger; NVDA+OMCL combined ~20.33%, buffer clean vs. the 25% trigger.

### Key assumptions that could break this model (unchanged from 8/27)
- Upside break: the 70% FY28 guide proves genuinely supply-constrained (a floor, not a ceiling).
- Downside break: AVGO/hyperscaler custom-silicon competition erodes the 75% gross-margin assumption in years 3-5.

---

## 2. Omnicell (OMCL) — price-roll update, model unchanged, discount at a new widest-recorded level

Price $33.075 (state.md, 9/10 ~09:38 ET, -1.68% on the day). No fresh WebSearch catalyst found this run beyond the already-known Q2 print and 10/29 next-earnings date.

Base case fair value **$53.89** (WACC 9%, g 3% — unchanged since 7/30) vs. $33.075 implies **~62.9% upside** — a new widest-recorded gap on this name, up from 9/9's ~61.8%.

### Verdict: **UNDERVALUED — widest mispricing on the book, still gated**
No fresh catalyst to act on (rule 1); the OMCL DCA accumulated-profit gate (per state.md, ~$2.44 of the $2.50 threshold still required as of 09:38 ET) remains the operative timing mechanism, not this desk's valuation call.

### Key assumptions that could break this model (unchanged)
- Upside break: the softer Q3/bookings guide proves conservative rather than a genuine slowdown.
- Downside break: continued high-amplitude, no-catalyst price action remains an argument for sizing discipline, not for revising this desk's valuation call.

---

## 3. Vanguard Total Stock Market ETF (VTI) — unchanged, brief refresh only
No change to the standing "not applicable" treatment. $373.54 (-0.54%). This desk has no fair-value view on VTI and defers entirely to BR/BW on sizing and drift-band status.

## 4. Vanguard Total International Stock ETF (VXUS) — unchanged, brief refresh only
No change to the standing "not applicable" treatment. $86.585 (-0.94%). No fair-value case to add or trim. Defer to BR/BW.

---

## 5. Energy Select Sector SPDR (XLE) — price-roll on 9/9's rebuilt composite, model unchanged this run

Price $65.49 (+0.28%, the sole green holding in the book today against the broader Hormuz-driven risk-off — the hedge thesis doing exactly its job). No fresh XOM/CVX-specific data point found this run to justify re-running the two-name composite; rolling forward 9/9's rebuild (WACC 10.5%, g 1.5%, weighted composite fair value ≈ $58.9/sh — see 9/9's report or git history for the full CVX+XOM build methodology).

vs. $65.49 → **gap ≈ -10.1% overvalued**, essentially flat vs. 9/9's -10.4% on a marginal price move.

### Verdict: **OVERVALUED, gap ≈ -10.1% — verdict and magnitude both unchanged**
No trim (hedge thesis intact and working — XLE is the only green name in the book today against a live Hormuz/tanker-war escalation), no add (still overvalued on the rebuilt composite). Standing self-directed ask unchanged: extend the composite beyond XOM+CVX to 5-8 names for a more complete basket read.

### Key assumptions that could break this model (unchanged from 9/9)
- Upside break: the war premium proves stickier than modeled (Brent holding $95+ through 2027).
- Downside break: a genuine, signed Hormuz de-escalation would collapse the war premium faster than modeled, widening the overvaluation gap.

---

## Cross-check with GS screener (analysts/gs-stock-screener.md, 2026-09-09 ~15:45 ET report)
GS's rank-1 slot remains XLE (already held) — no separate not-held name requires a build this cycle. GS's report independently reaches the same "no structural break" conclusion on GEHC's conference commentary that state.md's own 09:38 ET rule-5 re-read did, and separately flags the Patient Care Solutions strategic review as a new watch item without yet folding it into a valuation view — this desk's §0 rebuild is the first cross-desk attempt to actually price that disclosure rather than just flag it.

## Explicit read on trader's current positions (all six: NVDA, OMCL, VTI, VXUS, XLE, GEHC)
**GEHC**: hold, no trim, no add — **freshly rebuilt this run**; DCF gap widens to its largest yet (~10.8% undervalued), confirming rather than overriding the trader's own 09:38 ET decision. BW's fresh post-trigger risk read (reflecting the PCS disclosure) is the remaining rule-6 input before any add gets weighed.
**NVDA**: hold, no add, no trim — base-case DCF gap ~5.8% overvalued, narrower than last cycle on today's broad pullback.
**OMCL**: hold, no add from this desk's chair — DCF discount at a new widest-recorded level (~62.9%). The DCA plan's own profit-threshold gate remains the actual timing mechanism.
**VTI / VXUS**: hold, no valuation view — diversified core-sleeve holdings, not DCF calls. Defer to BR/BW on drift-band status.
**XLE**: hold, no trim, no add — composite fair value ≈ $58.9/sh, gap ≈ -10.1%, essentially flat vs. 9/9.

---

Sources:
- [GE HealthCare targets 3% to 4% organic sales growth and $4.80 to $5 adjusted EPS in 2026 while reviewing Patient Care Solutions options - Seeking Alpha](https://seekingalpha.com/news/4620626-ge-healthcare-targets-3-percent-to-4-percent-organic-sales-growth-and-4_80-to-5-adjusted-eps)
- [GE HealthCare could sell Patient Care Solutions biz as it reorganizes - MassDevice](https://www.massdevice.com/ge-healthcare-could-sell-patient-care-solutions-biz-as-it-reorganizes/)
- [GE Healthcare Considers Sale of Patient Care Solutions Unit - MDDI](https://www.mddionline.com/business/-better-parked-with-someone-else-ge-healthcare-reviews-patient-care-solutions-options)
- [GE HealthCare (GEHC) Q2 2026 Earnings Call Transcript - The Motley Fool](https://www.fool.com/earnings/call-transcripts/2026/07/30/ge-healthcare-gehc-q2-2026-earnings-call-transcript/)
- [GE HealthCare Technologies (GEHC) Stock Price & Overview - stockanalysis.com](https://stockanalysis.com/stocks/gehc/)
- [GE HealthCare Technologies (GEHC) Stock Forecast & Price Targets - stockanalysis.com](https://stockanalysis.com/stocks/gehc/forecast/)
- [US 10 Year Treasury Note Yield - Trading Economics](https://tradingeconomics.com/united-states/government-bond-yield)
- Internal: trading-experiment/state.md (09:38 ET), analysts/gs-stock-screener.md (9/9 ~15:45 ET), analysts/bw-risk-assessment.md (9/9 ~14:41 ET), analysts/br-portfolio-builder.md (9/9 ~16:14 ET), analysts/jpm-earnings-analyzer.md (9/10)
